← All Kura Oncology, INC filings

Kura Oncology, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KURA
Kura Oncology, INC
10-K: Kura Oncology Secures FDA Approval for KOMZIFTI in AML
Kura Oncology achieved a pivotal milestone with FDA approval and commercial launch of KOMZIFTI for relapsed or refractory NPM1-mutated AML, while advancing a diversified oncology pipeline.
NASDAQ
KURA
Kura Oncology, INC
10-K: Kura Oncology Announces Global Collaboration with Kyowa Kirin; Reports Positive Phase 2 Results for Ziftomenib
Kura Oncology partners with Kyowa Kirin in a global collaboration for ziftomenib, while also reporting positive topline results from its Phase 2 KOMET-001 trial.
NASDAQ
KURA
Kura Oncology, INC
10-K: Kura Oncology Reports 2023 Financial Results and Provides Clinical Pipeline Update
Kura Oncology's 2023 10-K filing details the company's financial status, clinical trial progress, and strategic direction, highlighting advancements in its precision medicine pipeline.